{"success":true,"data":{"pressRelease":{"id":"60095","rtpr_id":"nGNXbbGBtn","ticker":"PRE","exchange":"NASDAQ","all_tickers":["PRE"],"title":"Prenetics Announces Record Q1 2026 Results with IM8 Revenue Reaching a Record ~$16.7 Million in May, Implying ~$200 Million in Annualized Recurring Revenue","author":"Globe Newswire","published_at":"2026-06-10T12:30:00.986Z","article_body":"* Q1 2026 revenue of $36.0 million with IM8 revenue of $33.8 million, up 23.1%\nfrom IM8 revenue of $27.4 million in Q4 2025 and nearly 6x year-over-year from\nIM8 revenue of $5.7 million in Q1 2025\n* Raises full-year 2026 IM8 revenue guidance to $190 million to $210 million\n(previously $180 million to $200 million)\n* Projects Q2 2026 revenue of $46 million to $48 million, with IM8\ncontributing $44 million to $46 million, representing approximately 33%\nsequential quarterly growth for IM8\n* Fully divested digital asset holdings for $41.3 million (510 units at\n~$80,980)\n\n* Three new SKUs planned for Q4 2026 across Hydration, Creatine, and Kids’\nGummies\n* Appointed consumer supplements finance veteran Brian J. Rosin as Chief\nFinancial Officer of IM8\n* Latest investor deck can be found at https://ir.prenetics.com\nNEW YORK, June 10, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:\nPRE) (\"Prenetics\" or the \"Company\"), a leading consumer health sciences\ncompany and parent of the IM8 premium health and longevity brand, today\nannounced its financial results for the first quarter ended March 31, 2026.\nThese results supersede the preliminary unaudited results announced on May 14,\n2026 (the \"Preliminary Announcement\"). Revenue, gross profit, loss from\noperations, EBITDA(1) and Adjusted EBITDA(2) for the first quarter ended March\n31, 2026, as set forth in this press release, are consistent with the\npreliminary estimates in the Preliminary Announcement. Loss for the period\nreflects completion of the Company’s quarter-end closing procedures as\ndescribed below.\n\nFor the convenience of readers, this announcement consolidates the key\noperational, strategic and balance sheet information previously furnished in\nthe Preliminary Announcement, together with the Company's complete financial\nstatements for the first quarter ended March 31, 2026.\n\nComparison to Preliminary Announcement\n\nThe Q1 2026 results are consistent in all material respects with the\npreliminary estimates set out in the Preliminary Announcement. Revenue of\n$36.0 million, gross profit of $23.3 million, loss from operations of $8.9\nmillion, and adjusted EBITDA loss of $5.6 million are each consistent with the\npreliminary figures.\n\nLoss for the period of $23.1 million reflects completion of the Company’s\nquarter-end closing procedures, including the final valuation of (i) warrant\nliabilities associated with the Company's December 2025 warrant exchange\nprogram and (ii) share consideration received in connection with the disposal\nof the Europa 3PL business completed in January 2026. Loss for the period was\ndriven primarily by two non-cash, non-operating items: an unrealized\nfair-value loss on digital assets of approximately $9.8 million, reflecting\nthe decline in Bitcoin prices during the quarter, and a fair-value loss on\nwarrant liabilities of approximately $8.0 million, driven primarily by the\nappreciation of the Company’s share price, which increases the carrying\nvalue of the warrant liability. Neither item affects revenue, gross profit,\nloss from operations or adjusted EBITDA, and neither involves any cash\noutflow.\n\nQ1 2026 Financial Results\n\n Three Months Ended (Unaudited) \n March 31, December 31, March 31, \n 2026 2025 2025 \n (in thousands of U.S. dollars) \n Continuing operations \n Revenue $ 35,954 $ 33,288 $ 8,275 \n Gross profit 23,283 21,377 5,607 \n Loss from operations (8,866 ) (11,514 ) (5,971 ) \n EBITDA (23,177 ) (7,430 ) (11,074 ) \n Adjusted EBITDA (5,599 ) (1,836 ) (2,439 ) \n \n\nThe below tables set out our revenue and gross profit by business unit for the\nquarters ended March 31, 2026, December 31, 2025, and March 31, 2025.\n\n Three Months Ended (Unaudited) \n March 31, 2026 \n Revenue Gross profit Gross margin \n (in thousands of U.S. dollars) \n Continuing operations \n CircleDNA $ 2,172 $ 1,555 72 % \n IM8 33,782 21,728 64 % \n $ 35,954 $ 23,283 65 % \n \n\n\n\n Three Months Ended (Unaudited) \n December 31, 2025 \n Revenue Gross profit Gross margin \n (in thousands of U.S. dollars) \n Continuing operations \n CircleDNA $ 5,840 $ 4,864 83 % \n IM8 27,448 16,513 60 % \n $ 33,288 $ 21,377 64 % \n \n\n\n\n Three Months Ended (Unaudited) \n March 31, 2025 \n Revenue Gross profit Gross margin \n (in thousands of U.S. dollars) \n Continuing operations \n CircleDNA $ 2,543 $ 2,192 86 % \n IM8 5,732 3,415 60 % \n $ 8,275 $ 5,607 68 % \n \n\nIM8: A Breakout Global Brand\n\nIM8 continued to demonstrate strong global product-market fit and brand\nmomentum, with Q1 2026 revenue of approximately $33.8 million. Momentum has\naccelerated into the second quarter: IM8 monthly revenue for April 2026\nreached approximately $14.0 million, representing approximately 18.6%\nmonth-over-month growth, and reached a record of approximately $16.7 million\nin May 2026, representing approximately 19.3% further month-over-month growth\nand implying annualized recurring revenue(3) of approximately $200 million.\nIM8 monthly revenue in May 2026 represents approximately 42 times growth in\nmonthly revenue since IM8's launch in December 2024, with the brand now\nreaching consumers across 43 countries.\n\n\n\nIM8 – Key Performance Indicators\n\n Metric Q1 2026 Q4 2025 Growth \n Monthly Revenue (End of Period) $11.8 million $10.0 million +18% \n Quarterly Revenue $33.8 million $27.4 million +23% \n Total Customer Orders 220,000+ 230,000+ (4)% \n Total Servings Delivered 8.8 million+ 6.9 million+ +28% \n New Customer Average Order Value $240 $157 +53% \n Average Order Value (Last Month of Period) $159 $133 +20% \n New Customer Subscription Rate ~79% ~80% Maintained \n Gross Margin ~64% ~60% +4% \n \n\nIM8 delivered meaningful gross margin expansion in Q1 2026, improving from\napproximately 60% in Q4 2025 to approximately 64% in Q1 2026, an approximately\n400 basis point increase quarter-over-quarter. The improvement was driven by a\ncombination of scale-driven manufacturing efficiencies as production volumes\nincreased across the Daily Ultimate Essentials Pro and Daily Ultimate\nLongevity lines, renegotiated unit economics with key contract manufacturers\nand ingredient suppliers, a favorable product mix shift toward higher-margin\nSKUs and subscription orders, packaging optimization, and improved fulfillment\nand freight efficiencies as order density grew across our 43 international\nmarkets. The Company expects to maintain gross margin efficiencies through the\nbalance of 2026 as volumes scale further and supply chain initiatives mature.\n\nTotal servings delivered grew approximately 28% quarter-over-quarter to over\n8.8 million, reflecting accelerating consumer engagement and increased product\nconsumption across IM8’s global customer base. Total customer orders\ndeclined modestly quarter-over-quarter to approximately 220,000, due to\nIM8’s deliberate and strategic transition toward quarterly subscription\nplans, which consolidate three months of customer demand into a single, larger\norder. As a result, average servings per order increased approximately 33% in\nQ1 2026, consistent with broader quarterly plan adoption. On a cumulative\nbasis, IM8 has now delivered more than 43 million servings to customers\nworldwide since launch, and in May 2026 averaged more than 160,000 servings\ndelivered per day, reflecting the strength and consistency of underlying\nconsumption.\n\nGlobal Diversification of IM8 Revenue\n\nIM8 continues to expand its international reach, and by the end of Q1 2026,\nIM8 shipped to 43 countries, with over 60% of IM8 revenue generated outside\nthe United States. This international momentum provides a strong foundation\nfor continued global expansion in 2026.\n\nTop Five IM8 Markets (Q1 2026)\n\n Market Q1 2026 IM8 Revenue % of Total Q1 2026 IM8 Revenue \n United States $12.8M 38.7 % \n Canada $4.5M 13.7 % \n United Kingdom $3.2M 9.8 % \n Australia $1.9M 5.6 % \n Singapore $1.4M 4.2 % \n \n\nStrategic Evolution Toward Quarterly Subscriptions\n\nFollowing the initial rollout of quarterly subscription plans in the United\nStates in Q4 2025, IM8 expanded quarterly subscription availability across\ninternational markets in Q1 2026. This international rollout validated the\nCompany’s strategy to enhance cash flow, increase upfront customer\ncommitment, improve logistics efficiency, and enhance customer lifetime value\nacross a broader global customer base.\n\nThe impact of this transition has been substantial:\n* FY2025 average order value: approximately $110\n* Q4 2025 (last month of period) average order value: approximately $133\n* Q1 2026 (new customer) average order value: approximately $240\nIM8’s new customer average order value increased to approximately $240 in Q1\n2026, reflecting the broader adoption of quarterly subscription plans\nfollowing the international rollout, together with continued demand for\nhigher-value product bundles, including the Beckham Stack. Quarterly plans\nrepresented a meaningful portion of new customer mix in Q1 2026, with\napproximately half of Beckham Stack customers and more than one-third of Daily\nUltimate Essentials Pro customers choosing quarterly subscriptions.\n\nManagement Commentary\n\nDanny Yeung, Chief Executive Officer and Co-Founder, commented: “The\nmomentum behind IM8 is extraordinary. Q1 2026 was a defining quarter — IM8\nrevenue grew nearly 6x year-over-year and 23.1% sequentially over Q4 2025, and\nour quarterly subscription strategy delivered a step-change in customer\neconomics. The acceleration has continued into Q2 2026: IM8 monthly revenue\nreached approximately $14.0 million in April, and reached a record of\napproximately $16.7 million in May, implying annualized recurring revenue of\napproximately $200 million.\n\nBased on this trajectory, we currently expect Q2 2026 revenues of\napproximately $46 million to $48 million, with IM8 contributing approximately\n$44 million to $46 million, and we are raising our full-year 2026 IM8 revenue\nguidance to $190 million to $210 million, from our prior range of $180 million\nto $200 million. The strength of our underlying unit economics, the global\npull we are seeing from consumers across more than 40 markets, and the upside\nin new marketing channels give us strong conviction.\n\nLooking ahead, I am especially excited about our product roadmap. In Q4 2026,\nIM8 plans to launch new offerings in three meaningful categories with very\nlarge addressable markets — hydration, creatine, and kids’ gummies —\nextending the brand into high-growth segments. What we have built with David\nBeckham, our elite roster of athlete partners, and our world-class scientific\nadvisory board is becoming a category-defining global health brand. Q1 proved\nthe model. Q2 is proving the acceleration. The rest of 2026 will demonstrate\nthe scale of the opportunity ahead.”\n\nA World-Class Roster of Athlete Partners and Equity-Aligned Ambassadors\n\nA defining feature of the IM8 brand is its roster of world-class athlete\npartners, each of whom has a direct equity-based alignment with the\nCompany’s long-term success. Co-founded with David Beckham, IM8 is\nchampioned by World No. 1 tennis player Aryna Sabalenka, Formula 1 driver\nOllie Bearman of Haas F1 Team, and two-time NBA Most Valuable Player Giannis\nAntetokounmpo, each of whom holds equity in Prenetics. Most recently, IM8\nannounced a multi-year strategic partnership with Inter Miami CF, which\nincludes an equity stake for Inter Miami CF in Prenetics, together with name,\nimage and likeness rights for a minimum of four Inter Miami CF players,\nincluding Lionel Messi, and the establishment of an IM8 Nutrition Center at\nthe club’s training facility. The Company believes this equity-based\npartnership model creates deeper, longer-term alignment than traditional\nendorsement arrangements, while supporting global brand reach across some of\nthe most engaged sports audiences in the world.\n\nExpanding the IM8 Product Portfolio – New Q4 2026 Launches\n\nIM8 plans to extend its product portfolio in Q4 2026 with new offerings in\nthree adjacent categories: hydration, creatine, and kids’ gummies. These\ncategories represent large, fast-growing segments of the global consumer\nhealth market — the global hydration category is approximately $37 billion,\ngrowing 8% annually; the global creatine category is approximately $1.3\nbillion, growing 26% annually; and the global kids' supplements category is\napproximately $3.6 billion, growing 8% annually, according to Grand View\nResearch — and each is a natural extension of IM8’s daily nutrition\nplatform. Each launch will adhere to the same standards that define IM8’s\nflagship Daily Ultimate Essentials Pro product, including premium ingredient\nquality, science-backed formulation and rigorous third-party testing. The\nCompany believes these launches will broaden IM8’s addressable market,\nincrease customer lifetime value through additional household use cases, and\nsupport continued revenue diversification beyond IM8’s flagship SKU.\n\nA Strong, Debt-Free Balance Sheet\n\nPrenetics maintained a strong, debt-free balance sheet as of March 31, 2026,\nwith cash and cash equivalents of $56.0 million and no debt. The Company had\nnet current assets of $106.5 million as of March 31, 2026, up from $56.5\nmillion as of December 31, 2025. Prenetics held digital assets of $34.8\nmillion as of March 31, 2026. Subsequent to March 31, 2026, the Company\ndivested its digital asset holdings in full, selling 510 units for total cash\nproceeds of approximately $41.3 million, at an average price of approximately\n$80,980 per unit, which have been received by the Company.\n\nAs of May 31, 2026, the Company had estimated cash balances across its\naccounts of approximately $83.4 million. In addition, the Company held current\nfinancial assets measured at fair value through profit or loss, representing\ninvestments in investment funds, of approximately $50.2 million based on the\nlatest available valuations, and cash consideration held in escrow and\nholdback, recorded under other receivables, of approximately $6.1 million. As\nof May 31, 2026, the combined total of the Company’s estimated cash\nbalances, current financial assets measured at fair value through profit or\nloss, and cash consideration held in escrow and holdback, was approximately\n$139.7 million.\n\nReturning Capital to Shareholders\n\nOn March 6, 2026, the Company announced a $40 million share repurchase\nprogram. From program launch on March 6, 2026 through May 13, 2026, the\nCompany has repurchased 968,349 of its Class A Ordinary Shares in open-market\ntransactions for a total purchase price of approximately $19 million. The\nrepurchase program reflects the Board’s confidence in the long-term value of\nthe Company and complements continued investment in IM8’s growth\ninitiatives. The Company intends to continue executing repurchases under the\nauthorized program in a disciplined manner, subject to market conditions and\napplicable regulatory requirements.\n\nAdvancing Global Nutrition – Partnership with Vitamin Angels\n\nIn April 2026, Prenetics announced a global partnership between IM8 and\nVitamin Angels, a leading global public health nonprofit with a 31-year track\nrecord, a four-star Charity Navigator rating, and the infrastructure to reach\nmore than 74 million women and children annually across 65+ countries. Under\nthe partnership, IM8 has committed to impacting 400,000 pregnant women,\ninfants, and children under five in underserved communities during the first\nyear, with a long-term goal to impact millions of lives through sustained\nfunding and awareness. The partnership extends IM8’s mission beyond premium\nnutrition to address malnutrition among the world’s most vulnerable\npopulations.\n\nStrengthening IM8 Leadership for the Next Phase of Growth\n\nIM8 also strengthened its leadership team with the appointment of Brian J.\nRosin as Chief Financial Officer of IM8. Mr. Rosin is based in the United\nStates and brings significant experience across consumer health, e-commerce\noperations, finance, and strategic execution, having previously served as CFO\nof Wellbeam Consumer Health and NATURELO Premium Supplements. His appointment\nadds dedicated financial and operational leadership to support IM8’s next\nphase of global growth, disciplined execution, and strategic initiatives.\n\nOutlook\n\nIM8 generated revenue of approximately $30.7 million for the two months ended\nMay 31, 2026. The Company expects Q2 2026 revenue in the range of\napproximately $46 million to $48 million, with IM8 contributing approximately\n$44 million to $46 million, representing approximately 33% sequential\nquarterly growth for IM8. The Company is raising its full-year 2026 IM8\nrevenue guidance to $190 million to $210 million (previously $180 million to\n$200 million). These guidance ranges are consistent with those set out in the\nPreliminary Announcement and reflect management’s current estimates as of\nthe date of this announcement.\n\nAbout Prenetics\n\nPrenetics (NASDAQ: PRE) is a leading health sciences company dedicated to\nadvancing human health and longevity. The Company’s flagship consumer brand,\nIM8, co-founded with David Beckham and championed by World No. 1 tennis player\nAryna Sabalenka, is redefining the premium daily nutrition category through\nscience-backed formulations and global brand partnerships. Since its launch,\nIM8 has become one of the fastest-growing brands in consumer health, achieving\nan impressive milestone of surpassing $100 million in annualized recurring\nrevenue within just 11 months of operations, and is now sold in more than 40\ncountries worldwide.\n\nAbout IM8\n\nIM8 is the pinnacle of premium core nutrition, born from a collaboration\nbetween David Beckham as a co-founding partner, and an elite team of\nscientists spanning medical professionals, academia and space science.\nCombining cutting-edge science with nature’s most potent ingredients, IM8\ndelivers a holistic, science-backed approach to health, empowering you to live\nyour most vibrant life. IM8’s flagship product, Daily Ultimate Essentials\nPro, is an all-in-one powder supplement engineered to replace 16 different\nsupplements in a delicious drink and is NSF Certified for Sport, non-GMO,\nvegan, free from common allergens, and contains no artificial flavors, colors\nor sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading\nglobal health sciences company dedicated to advancing consumer health. To\nlearn more about IM8, please visit www.IM8health.com.\n\nInvestor Relations Contact\n\ninvestors@prenetics.com \nPRE@mzgroup.us \n\nAngela Cheung\nInvestor Relations / Corporate Finance\nangela.hm.cheung@prenetics.com \n\nForward-Looking Statements\n\nThis press release contains forward-looking statements. These statements are\nmade under the “safe harbor” provisions of the U.S. Private Securities\nLitigation Reform Act of 1995. Statements that are not historical facts,\nincluding statements about the Company’s goals, targets, projections,\noutlooks, beliefs, expectations, strategy, plans, objectives of management for\nfuture operations of the Company, and growth opportunities are forward-looking\nstatements. Our guidance reflects management’s current estimates and\nassumptions as of the date of this release, is subject to significant risks\nand uncertainties, and is not a guarantee of future performance. Actual\nresults may differ materially. In some cases, forward-looking statements can\nbe identified by words or phrases such as “may,” “will,” “expect,”\n“anticipate,” “target,” “aim,” “estimate,” “intend,”\n“plan,” “believe,” “potential,” “continue,” “is/are likely\nto,” “guidance,” “outlook,” “forecast,” or other similar\nexpressions. Forward-looking statements are based upon estimates and forecasts\nand reflect the views, assumptions, expectations, and opinions of the Company,\nwhich involve inherent risks and uncertainties, and therefore they should not\nbe relied upon as being necessarily indicative of future results. A number of\nfactors could cause actual results to differ materially from those contained\nin any forward-looking statement, including but not limited to: the Company\nmay not be able to maintain and enhance its IM8 business and brand if it\nsuffers negative publicity or fails to maintain a strong base of engaged\ncustomers and content creators, or otherwise fails to meet customers’\nexpectations; the Company’s ability to further develop and grow its\nbusiness, including new products and services; and its ability to identify and\nexecute on M&A opportunities. In addition to the foregoing factors, you should\nalso carefully consider the other risks and uncertainties described in the\n“Risk Factors” section of the Company’s most recent registration\nstatement and the prospectus therein, and the other documents filed by the\nCompany from time to time with the U.S. Securities and Exchange Commission.\nUnless otherwise specified, all information provided in this press release is\nas of the date of this press release, and the Company does not undertake any\nduty to update such information, except as required under applicable law.\nNothing in this press release constitutes an offer to sell, or the\nsolicitation of an offer to buy, any securities of the Company.\n\nBasis of Presentation\n\nFigures for prior periods have been re-presented in accordance with IFRS 5\nNon-current Assets Held for Sale and Discontinued Operations (“IFRS 5”).\nAs part of the Group’s strategic repositioning to focus its resources and\ncapital allocation on its core consumer health and prevention businesses, the\nGroup has divested or exited certain non-core businesses and investments,\nincluding ACT Genomics, Europa and Insighta.\n\nIn June 2025, the Group determined that ACT Genomics Holdings Company Limited\n(“ACT Genomics”) met the criteria to be classified as held for sale and a\ndiscontinued operation, following the signing of a definitive sale and\npurchase agreement with Delta Electronics, Inc. The divestment of ACT Genomics\nwas completed on October 1, 2025, and its results have been excluded from the\nGroup’s continuing operations thereafter.\n\nThe Group also completed the divestiture of substantially all of the assets of\nits Europa business in January 2026. Accordingly, Europa’s results are\nincluded in the Group’s financial results only up to the date of completion\nof the divestiture and are excluded from the Group’s continuing operations\nthereafter.\n\nIn February 2026, the Group completed the disposal of its remaining equity\ninterest in Insighta Holdings Limited (“Insighta”). Accordingly, the\nGroup’s share of results from Insighta is included only up to the date of\ncompletion of the disposal.\n\nIn accordance with IFRS 5, the results of discontinued operations are\npresented separately from the Group’s continuing operations (comprising IM8\nand CircleDNA) in the unaudited consolidated statements of profit or loss and\nother comprehensive income, and comparative figures for those statements have\nbeen re-presented accordingly.\n\nThe financial information presented in this press release was unaudited.\nUnaudited non-IFRS financial measures have been provided in this press\nrelease. An explanation of these measures is also included below under the\nheading “Unaudited Non-IFRS Financial Measures”.\n\nUnaudited Non-IFRS Financial Measures\n\nTo supplement the Company’s consolidated financial statements prepared in\naccordance with IFRS Accounting Standards, the Company is providing the\nfollowing non-IFRS measures: EBITDA and adjusted EBITDA. These non-IFRS\nfinancial measures are not based on any standardized methodology prescribed by\nIFRS Accounting Standards and are not necessarily comparable to\nsimilarly-titled measures presented by other companies. Management believes\nthese non-IFRS financial measures are useful to investors in evaluating the\nCompany’s ongoing operating results and trends.\n\nEBITDA is defined as net loss before (1) depreciation and amortization, (2)\ninterest income, (3) other finance costs, and (4) income tax expense.\n\nAdjusted EBITDA is defined as EBITDA further adjusted to exclude (1)\namortization of deferred expenses, (2) equity-settled share-based payment\nexpenses, (3) non-recurring expenses related to acquisition, disposal and\nfundraising, (4) strategic realignment expenses, (5) exchange gain or loss,\nnet, (6) fair value loss/(gain) on financial assets at fair value through\nprofit or loss, (7) fair value loss on warrant liabilities, (8) gain on\nwarrant exchange, (9) unrealized fair value loss on digital asset, and (10)\n(profit)/loss from discontinued operations, net of tax.\n\nIn addition, other companies, including companies in the same industry, may\nnot use the same non-IFRS measures or may calculate these metrics in a\ndifferent manner than management, or may use other financial measures to\nevaluate their performance, all of which could reduce the usefulness of these\nnon-IFRS measures as comparative measures. Because of these limitations, the\nCompany’s non-IFRS financial measures should not be considered in isolation\nfrom, or as a substitute for, financial information prepared in accordance\nwith IFRS Accounting Standards.\n\nInvestors are encouraged to review the breakdown provided in the non-IFRS\nreconciliation set forth in the below table captioned “Reconciliation of\nloss for the period under IFRS Accounting Standards and adjusted EBITDA\n(Non-IFRS).”\n\nPRENETICS GLOBAL LIMITED\nUnaudited consolidated statements of financial position\n(All amounts in thousands of U.S. dollars (“$”))\n\n March 31, December 31, \n 2026 2025 \n (Unaudited) (Audited) \n Assets \n Property, plant and equipment $ 594 $ 1,763 \n Intangible assets 40 66 \n Digital assets 34,799 44,629 \n Goodwill — 1,379 \n Interests in equity-accounted investees — 66,109 \n Financial assets at fair value through profit or loss - non-current 2,338 252 \n Other non-current assets 5,423 6,678 \n Non-current assets 43,194 120,876 \n Inventories 14,198 7,032 \n Trade receivables 2,529 2,978 \n Deposits, prepayments and other receivables 9,346 11,860 \n Amount due from a related company — 4 \n Financial assets at fair value through profit or loss - current 50,018 31,192 \n Cash and cash equivalents 56,017 32,131 \n Current assets 132,108 85,197 \n Total assets $ 175,302 $ 206,073 \n Liabilities \n Deferred tax liabilities $ 8 $ 8 \n Warrant liabilities 28,354 20,319 \n Lease liabilities - non-current 50 437 \n Other non-current liabilities 228 230 \n Non-current liabilities 28,640 20,994 \n Trade payables 1,961 3,142 \n Accrued expenses and other current liabilities 20,293 21,124 \n Contract liabilities 2,948 3,086 \n Lease liabilities - current 407 1,330 \n Tax payable 31 31 \n Current liabilities 25,640 28,713 \n Total liabilities 54,280 49,707 \n Equity \n Class A ordinary shares 23 23 \n Class B ordinary shares 2 2 \n Reserves 121,090 156,434 \n Total equity attributable to equity shareholders of the Company 121,115 156,459 \n Non-controlling interests (93 (93 \n Total equity 121,022 156,366 \n Total equity and liabilities $ 175,302 $ 206,073 \n \n\nPRENETICS GLOBAL LIMITED\nUnaudited consolidated statements of profit or loss and other comprehensive\nincome\n(All amounts in thousands of U.S. dollars (“$”) unless otherwise\nindicated)\n\n Three Months Ended \n March 31, December 31, March 31, \n 2026 2025 2025 \n (Unaudited) (Unaudited) (Unaudited) \n Continuing operations \n Revenue $ 35,954 $ 33,288 $ 8,275 \n Direct costs (12,671 ) (11,911 ) (2,668 ) \n Gross profit 23,283 21,377 5,607 \n Other income and other net gain 840 212 204 \n Selling and marketing expenses (4) (22,205 ) (16,090 ) (4,126 ) \n Research and development expenses (4) (1,443 ) (743 ) (2,007 ) \n Administrative and other operating expenses (4) (9,341 ) (16,270 ) (5,649 ) \n Loss from operations (8,866 ) (11,514 ) (5,971 ) \n Fair value (loss)/gain on financial assets at fair value through profit or loss (568 ) 879 — \n Gain on warrant exchange — 36,657 — \n Fair value loss on warrant liabilities (8,035 ) (17,339 ) (63 ) \n Unrealized fair value loss on digital assets (9,830 ) (9,725 ) — \n Other finance costs (9 ) (12 ) (18 ) \n Loss before taxation (27,308 ) (1,054 ) (6,052 ) \n Income tax expense (28 ) (37 ) (20 ) \n Loss from continuing operations (27,336 ) (1,091 ) (6,072 ) \n Discontinued operation \n Profit/(loss) from discontinued operation, net of tax (5) 4,231 (6,451 ) (4,944 ) \n Loss for the period (23,105 ) (7,542 ) (11,016 ) \n Other comprehensive (expense)/income for the period \n Items that will not be reclassified subsequently to profit or loss: \n Share of other comprehensive (expense)/income of equity-accounted investees (167 ) 40 (36 ) \n Unrealized fair value loss on digital asset — (1,351 ) — \n Item that may be reclassified subsequently to profit or loss: \n Reclassification of cumulative translation reserve upon disposal of foreign operations — (74 ) — \n Exchange difference on translation of foreign operations (198 ) 328 103 \n Other comprehensive (expense)/income for the period (365 ) (1,057 ) 67 \n Total comprehensive expense for the period $ (23,470 ) $ (8,599 ) $ (10,949 ) \n Loss attributable to: \n Equity shareholders of Prenetics $ (23,104 ) $ (7,500 ) $ (10,390 ) \n Non-controlling interests — (42 ) (626 ) \n $ (23,104 ) $ (7,542 ) $ (11,016 ) \n Total comprehensive expense attributable to: \n Equity shareholders of Prenetics $ (23,470 ) $ (8,592 ) $ (10,243 ) \n Non-controlling interests — (7 ) (706 ) \n $ (23,470 ) $ (8,599 ) $ (10,949 ) \n Loss per share: \n Basic $ (1.36 ) $ (0.47 ) $ (0.80 ) \n Diluted (1.36 ) (0.47 ) (0.80 ) \n Loss per share - Continuing operations: \n Basic (1.61 ) (0.07 ) (0.44 ) \n Diluted (1.61 ) (0.07 ) (0.44 ) \n Weighted average number of common shares: \n Basic 16,982,575 16,034,309 13,003,881 \n Diluted 16,982,575 16,034,309 13,003,881 \n \n\nPRENETICS GLOBAL LIMITED\nUnaudited consolidated statements of cash flows\n(All amounts in thousands of U.S. dollars (“$”))\n\n Three Months Ended \n March 31, March 31, \n 2026 2025 \n (Unaudited ) (Unaudited ) \n Cash flows from operating activities \n Loss for the year (23,105 ) (11,016 ) \n Adjustments for: \n Bank interest income (294 ) (440 ) \n Depreciation 159 893 \n Amortization of intangible assets 25 239 \n Other finance costs 9 69 \n Fair value loss on financial assets at fair value through profit or loss 568 — \n Fair value loss on warrant liabilities 8,035 63 \n Unrealized fair value loss on digital asset 9,830 — \n Net foreign exchange losses (20 ) (196 ) \n Gain on disposal of assets (253 ) — \n Write-off on inventories (32 ) 667 \n Gain on disposal of an equity-accounted investee (4,172 ) — \n Share of loss of equity-accounted investees 113 309 \n Equity-settled share-based payment expenses 1,242 1,119 \n Income tax expense/(credit) 28 (64 ) \n (7,867 ) (8,357 ) \n Changes in: \n Decrease in deferred expenses — 2,057 \n Increase in inventories (7,134 ) (711 ) \n Decrease in trade receivables 451 779 \n (Increase)/decrease in deposits, prepayments and other receivables 2,874 1,043 \n Decrease in amounts due from related companies 4 — \n Decrease in other non-current assets 1,255 118 \n (Decrease)/increase in trade payables (1,179 ) 469 \n (Decrease)/increase in accrued expenses and other current liabilities (358 ) 926 \n Decrease in contract liabilities (138 ) (300 ) \n Decrease in other non-current liabilities (4 ) (1 ) \n Cash used in operating activities (12,096 ) (3,977 ) \n Income taxes paid (28 ) — \n Net cash used in operating activities (12,124 ) (3,977 ) \n Cash flows from investing activities \n Payment for purchase of financial assets at fair value through profit or loss (19,876 ) — \n Net cash inflow from disposal of an equity-accounted investee 69,000 — \n Interest received 294 440 \n Net cash from investing activities 49,418 440 \n Cash flows from financing activities \n Capital element of lease rentals paid (142 ) (622 ) \n Interest element of lease rentals paid (9 ) (69 ) \n Proceeds from public placement (13,117 ) — \n Net cash used in financing activities (13,268 ) (691 ) \n Net increase/(decrease) in cash and cash equivalents 24,026 (4,228 ) \n Cash and cash equivalents at the beginning of the period 32,131 52,251 \n Effect of foreign exchange rate changes (140 ) (57 ) \n Cash and cash equivalents at the end of the period 56,017 47,966 \n \n\nPRENETICS GLOBAL LIMITED\nUnaudited Non-IFRS Financial Measures\n(All amounts in thousands of U.S. dollars (“$”))\n\nReconciliation of loss for the period under IFRS Accounting Standards and\nadjusted EBITDA (Non-IFRS)\n\n Three Months Ended \n March 31, December 31, March 31, \n 2026 2025 2025 \n (Unaudited ) (Unaudited ) (Unaudited ) \n Loss for the period under IFRS Accounting Standards $ (23,104 ) $ (7,542 ) $ (11,016 ) \n Depreciation and amortization 184 273 326 \n Interest income (294 ) (210 ) (422 ) \n Other finance costs 9 12 18 \n Income tax expense 28 37 20 \n EBITDA (23,177 ) (7,430 ) (11,074 ) \n Amortization of deferred expenses — — 2,057 \n Equity-settled share-based payment expenses 1,242 1,299 1,167 \n Non-recurring expenses related to acquisition, disposal and fundraising 953 4,366 126 \n Strategic realignment expenses 1,252 3,750 2 \n Exchange gain or loss, net (71 ) 200 276 \n Fair value loss/(gain) on financial assets at fair value through profit or loss 568 (879 ) — \n Fair value loss on warrant liabilities 8,035 17,339 63 \n Gain on warrant exchange — (36,657 ) — \n Unrealized fair value loss on digital assets 9,830 9,725 — \n (Profit)/loss from discontinued operation, net of tax (4,231 ) 6,451 4,944 \n Adjusted EBITDA $ (5,599 ) $ (1,836 ) $ (2,439 ) \n \n\n\n\n Three Months Ended \n March 31, December 31, March 31, \n 2026 2025 2025 \n (Unaudited) (Unaudited) (Unaudited) \n Continuing operations \n Selling and marketing expenses $ 27 $ 24 $ 1 \n Research and development expenses 226 90 467 \n Administrative and other operating expenses 746 444 456 \n Total employee equity-settled share-based payment expenses $ 999 $ 558 $ 924 \n \n\n(1 )EBITDA is a non-IFRS financial measure used by us to measure the strength\nof our core financial and operating performance. EBITDA excludes (1)\ndepreciation and amortization, (2) interest income, (3) other finance costs,\nand (4) income tax expense. For more information regarding this non-IFRS\nfinancial measure, see \"Unaudited Non-IFRS Financial Measures.\"\n(2 )Adjusted EBITDA is a non-IFRS financial measure used by us to measure the\nstrength of our core financial and operating performance. Adjusted EBITDA\nrepresents EBITDA further adjusted to exclude (1) amortization of deferred\nexpenses, (2) equity-settled share-based payment expenses, (3) non-recurring\nexpenses related to acquisition, disposal and fundraising, (4) strategic\nrealignment expenses, (5) exchange gain or loss, net, (6) fair value\nloss/(gain) on financial assets at fair value through profit or loss, (7) fair\nvalue loss on warrant liabilities, (8) gain on warrant exchange, (9)\nunrealized fair value loss on digital asset, and (10) (profit)/loss from\ndiscontinued operations, net of tax. These adjustments are made for items that\nmay not be indicative of our business performance, including non-cash and/or\nnon-recurring items. For more information regarding this non-IFRS financial\nmeasure, see \"Unaudited Non-IFRS Financial Measures.\"\n(3 )The Company uses annualized recurring revenue (“ARR”) as a key\noperating metric and is calculated by multiplying the monthly revenue from the\nlast month of a given period by 12.\n(4) Includes equity-settled share-based payment expenses from continuing\noperations as follows:\n(5) ACT Genomics, Europa and Insighta are classified as discontinued\noperations in accordance with IFRS 5. The results of the discontinued\noperations have been presented separately from the continuing operations in\nthe consolidated statements of profit or loss and other comprehensive income.\n\nA photo accompanying this announcement is available at\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/1a9e11ac-9f38-4820-84e0-218e21ce0f7d\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/106dbe1a-a6e1-49d9-97a2-c5609258bdc7)\nIM8 Monthly Revenue ($M) \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1a9e11ac-9f38-4820-84e0-218e21ce0f7d/en)\n~42x ARR Growth\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbbGBtn","title":"Prenetics Announces Record Q1 2026 Results with IM8 Revenue Reaching a Record ~$16.7 Million in May, Implying ~$200 Million in Annualized Recurring Revenue","author":"Globe Newswire","ticker":"PRE","created":"2026-06-10T12:30:00.986Z","tickers":["PRE"],"exchange":"NASDAQ","article_body":"* Q1 2026 revenue of $36.0 million with IM8 revenue of $33.8 million, up 23.1%\nfrom IM8 revenue of $27.4 million in Q4 2025 and nearly 6x year-over-year from\nIM8 revenue of $5.7 million in Q1 2025\n* Raises full-year 2026 IM8 revenue guidance to $190 million to $210 million\n(previously $180 million to $200 million)\n* Projects Q2 2026 revenue of $46 million to $48 million, with IM8\ncontributing $44 million to $46 million, representing approximately 33%\nsequential quarterly growth for IM8\n* Fully divested digital asset holdings for $41.3 million (510 units at\n~$80,980)\n\n* Three new SKUs planned for Q4 2026 across Hydration, Creatine, and Kids’\nGummies\n* Appointed consumer supplements finance veteran Brian J. Rosin as Chief\nFinancial Officer of IM8\n* Latest investor deck can be found at https://ir.prenetics.com\nNEW YORK, June 10, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:\nPRE) (\"Prenetics\" or the \"Company\"), a leading consumer health sciences\ncompany and parent of the IM8 premium health and longevity brand, today\nannounced its financial results for the first quarter ended March 31, 2026.\nThese results supersede the preliminary unaudited results announced on May 14,\n2026 (the \"Preliminary Announcement\"). Revenue, gross profit, loss from\noperations, EBITDA(1) and Adjusted EBITDA(2) for the first quarter ended March\n31, 2026, as set forth in this press release, are consistent with the\npreliminary estimates in the Preliminary Announcement. Loss for the period\nreflects completion of the Company’s quarter-end closing procedures as\ndescribed below.\n\nFor the convenience of readers, this announcement consolidates the key\noperational, strategic and balance sheet information previously furnished in\nthe Preliminary Announcement, together with the Company's complete financial\nstatements for the first quarter ended March 31, 2026.\n\nComparison to Preliminary Announcement\n\nThe Q1 2026 results are consistent in all material respects with the\npreliminary estimates set out in the Preliminary Announcement. Revenue of\n$36.0 million, gross profit of $23.3 million, loss from operations of $8.9\nmillion, and adjusted EBITDA loss of $5.6 million are each consistent with the\npreliminary figures.\n\nLoss for the period of $23.1 million reflects completion of the Company’s\nquarter-end closing procedures, including the final valuation of (i) warrant\nliabilities associated with the Company's December 2025 warrant exchange\nprogram and (ii) share consideration received in connection with the disposal\nof the Europa 3PL business completed in January 2026. Loss for the period was\ndriven primarily by two non-cash, non-operating items: an unrealized\nfair-value loss on digital assets of approximately $9.8 million, reflecting\nthe decline in Bitcoin prices during the quarter, and a fair-value loss on\nwarrant liabilities of approximately $8.0 million, driven primarily by the\nappreciation of the Company’s share price, which increases the carrying\nvalue of the warrant liability. Neither item affects revenue, gross profit,\nloss from operations or adjusted EBITDA, and neither involves any cash\noutflow.\n\nQ1 2026 Financial Results\n\n Three Months Ended (Unaudited) \n March 31, December 31, March 31, \n 2026 2025 2025 \n (in thousands of U.S. dollars) \n Continuing operations \n Revenue $ 35,954 $ 33,288 $ 8,275 \n Gross profit 23,283 21,377 5,607 \n Loss from operations (8,866 ) (11,514 ) (5,971 ) \n EBITDA (23,177 ) (7,430 ) (11,074 ) \n Adjusted EBITDA (5,599 ) (1,836 ) (2,439 ) \n \n\nThe below tables set out our revenue and gross profit by business unit for the\nquarters ended March 31, 2026, December 31, 2025, and March 31, 2025.\n\n Three Months Ended (Unaudited) \n March 31, 2026 \n Revenue Gross profit Gross margin \n (in thousands of U.S. dollars) \n Continuing operations \n CircleDNA $ 2,172 $ 1,555 72 % \n IM8 33,782 21,728 64 % \n $ 35,954 $ 23,283 65 % \n \n\n\n\n Three Months Ended (Unaudited) \n December 31, 2025 \n Revenue Gross profit Gross margin \n (in thousands of U.S. dollars) \n Continuing operations \n CircleDNA $ 5,840 $ 4,864 83 % \n IM8 27,448 16,513 60 % \n $ 33,288 $ 21,377 64 % \n \n\n\n\n Three Months Ended (Unaudited) \n March 31, 2025 \n Revenue Gross profit Gross margin \n (in thousands of U.S. dollars) \n Continuing operations \n CircleDNA $ 2,543 $ 2,192 86 % \n IM8 5,732 3,415 60 % \n $ 8,275 $ 5,607 68 % \n \n\nIM8: A Breakout Global Brand\n\nIM8 continued to demonstrate strong global product-market fit and brand\nmomentum, with Q1 2026 revenue of approximately $33.8 million. Momentum has\naccelerated into the second quarter: IM8 monthly revenue for April 2026\nreached approximately $14.0 million, representing approximately 18.6%\nmonth-over-month growth, and reached a record of approximately $16.7 million\nin May 2026, representing approximately 19.3% further month-over-month growth\nand implying annualized recurring revenue(3) of approximately $200 million.\nIM8 monthly revenue in May 2026 represents approximately 42 times growth in\nmonthly revenue since IM8's launch in December 2024, with the brand now\nreaching consumers across 43 countries.\n\n\n\nIM8 – Key Performance Indicators\n\n Metric Q1 2026 Q4 2025 Growth \n Monthly Revenue (End of Period) $11.8 million $10.0 million +18% \n Quarterly Revenue $33.8 million $27.4 million +23% \n Total Customer Orders 220,000+ 230,000+ (4)% \n Total Servings Delivered 8.8 million+ 6.9 million+ +28% \n New Customer Average Order Value $240 $157 +53% \n Average Order Value (Last Month of Period) $159 $133 +20% \n New Customer Subscription Rate ~79% ~80% Maintained \n Gross Margin ~64% ~60% +4% \n \n\nIM8 delivered meaningful gross margin expansion in Q1 2026, improving from\napproximately 60% in Q4 2025 to approximately 64% in Q1 2026, an approximately\n400 basis point increase quarter-over-quarter. The improvement was driven by a\ncombination of scale-driven manufacturing efficiencies as production volumes\nincreased across the Daily Ultimate Essentials Pro and Daily Ultimate\nLongevity lines, renegotiated unit economics with key contract manufacturers\nand ingredient suppliers, a favorable product mix shift toward higher-margin\nSKUs and subscription orders, packaging optimization, and improved fulfillment\nand freight efficiencies as order density grew across our 43 international\nmarkets. The Company expects to maintain gross margin efficiencies through the\nbalance of 2026 as volumes scale further and supply chain initiatives mature.\n\nTotal servings delivered grew approximately 28% quarter-over-quarter to over\n8.8 million, reflecting accelerating consumer engagement and increased product\nconsumption across IM8’s global customer base. Total customer orders\ndeclined modestly quarter-over-quarter to approximately 220,000, due to\nIM8’s deliberate and strategic transition toward quarterly subscription\nplans, which consolidate three months of customer demand into a single, larger\norder. As a result, average servings per order increased approximately 33% in\nQ1 2026, consistent with broader quarterly plan adoption. On a cumulative\nbasis, IM8 has now delivered more than 43 million servings to customers\nworldwide since launch, and in May 2026 averaged more than 160,000 servings\ndelivered per day, reflecting the strength and consistency of underlying\nconsumption.\n\nGlobal Diversification of IM8 Revenue\n\nIM8 continues to expand its international reach, and by the end of Q1 2026,\nIM8 shipped to 43 countries, with over 60% of IM8 revenue generated outside\nthe United States. This international momentum provides a strong foundation\nfor continued global expansion in 2026.\n\nTop Five IM8 Markets (Q1 2026)\n\n Market Q1 2026 IM8 Revenue % of Total Q1 2026 IM8 Revenue \n United States $12.8M 38.7 % \n Canada $4.5M 13.7 % \n United Kingdom $3.2M 9.8 % \n Australia $1.9M 5.6 % \n Singapore $1.4M 4.2 % \n \n\nStrategic Evolution Toward Quarterly Subscriptions\n\nFollowing the initial rollout of quarterly subscription plans in the United\nStates in Q4 2025, IM8 expanded quarterly subscription availability across\ninternational markets in Q1 2026. This international rollout validated the\nCompany’s strategy to enhance cash flow, increase upfront customer\ncommitment, improve logistics efficiency, and enhance customer lifetime value\nacross a broader global customer base.\n\nThe impact of this transition has been substantial:\n* FY2025 average order value: approximately $110\n* Q4 2025 (last month of period) average order value: approximately $133\n* Q1 2026 (new customer) average order value: approximately $240\nIM8’s new customer average order value increased to approximately $240 in Q1\n2026, reflecting the broader adoption of quarterly subscription plans\nfollowing the international rollout, together with continued demand for\nhigher-value product bundles, including the Beckham Stack. Quarterly plans\nrepresented a meaningful portion of new customer mix in Q1 2026, with\napproximately half of Beckham Stack customers and more than one-third of Daily\nUltimate Essentials Pro customers choosing quarterly subscriptions.\n\nManagement Commentary\n\nDanny Yeung, Chief Executive Officer and Co-Founder, commented: “The\nmomentum behind IM8 is extraordinary. Q1 2026 was a defining quarter — IM8\nrevenue grew nearly 6x year-over-year and 23.1% sequentially over Q4 2025, and\nour quarterly subscription strategy delivered a step-change in customer\neconomics. The acceleration has continued into Q2 2026: IM8 monthly revenue\nreached approximately $14.0 million in April, and reached a record of\napproximately $16.7 million in May, implying annualized recurring revenue of\napproximately $200 million.\n\nBased on this trajectory, we currently expect Q2 2026 revenues of\napproximately $46 million to $48 million, with IM8 contributing approximately\n$44 million to $46 million, and we are raising our full-year 2026 IM8 revenue\nguidance to $190 million to $210 million, from our prior range of $180 million\nto $200 million. The strength of our underlying unit economics, the global\npull we are seeing from consumers across more than 40 markets, and the upside\nin new marketing channels give us strong conviction.\n\nLooking ahead, I am especially excited about our product roadmap. In Q4 2026,\nIM8 plans to launch new offerings in three meaningful categories with very\nlarge addressable markets — hydration, creatine, and kids’ gummies —\nextending the brand into high-growth segments. What we have built with David\nBeckham, our elite roster of athlete partners, and our world-class scientific\nadvisory board is becoming a category-defining global health brand. Q1 proved\nthe model. Q2 is proving the acceleration. The rest of 2026 will demonstrate\nthe scale of the opportunity ahead.”\n\nA World-Class Roster of Athlete Partners and Equity-Aligned Ambassadors\n\nA defining feature of the IM8 brand is its roster of world-class athlete\npartners, each of whom has a direct equity-based alignment with the\nCompany’s long-term success. Co-founded with David Beckham, IM8 is\nchampioned by World No. 1 tennis player Aryna Sabalenka, Formula 1 driver\nOllie Bearman of Haas F1 Team, and two-time NBA Most Valuable Player Giannis\nAntetokounmpo, each of whom holds equity in Prenetics. Most recently, IM8\nannounced a multi-year strategic partnership with Inter Miami CF, which\nincludes an equity stake for Inter Miami CF in Prenetics, together with name,\nimage and likeness rights for a minimum of four Inter Miami CF players,\nincluding Lionel Messi, and the establishment of an IM8 Nutrition Center at\nthe club’s training facility. The Company believes this equity-based\npartnership model creates deeper, longer-term alignment than traditional\nendorsement arrangements, while supporting global brand reach across some of\nthe most engaged sports audiences in the world.\n\nExpanding the IM8 Product Portfolio – New Q4 2026 Launches\n\nIM8 plans to extend its product portfolio in Q4 2026 with new offerings in\nthree adjacent categories: hydration, creatine, and kids’ gummies. These\ncategories represent large, fast-growing segments of the global consumer\nhealth market — the global hydration category is approximately $37 billion,\ngrowing 8% annually; the global creatine category is approximately $1.3\nbillion, growing 26% annually; and the global kids' supplements category is\napproximately $3.6 billion, growing 8% annually, according to Grand View\nResearch — and each is a natural extension of IM8’s daily nutrition\nplatform. Each launch will adhere to the same standards that define IM8’s\nflagship Daily Ultimate Essentials Pro product, including premium ingredient\nquality, science-backed formulation and rigorous third-party testing. The\nCompany believes these launches will broaden IM8’s addressable market,\nincrease customer lifetime value through additional household use cases, and\nsupport continued revenue diversification beyond IM8’s flagship SKU.\n\nA Strong, Debt-Free Balance Sheet\n\nPrenetics maintained a strong, debt-free balance sheet as of March 31, 2026,\nwith cash and cash equivalents of $56.0 million and no debt. The Company had\nnet current assets of $106.5 million as of March 31, 2026, up from $56.5\nmillion as of December 31, 2025. Prenetics held digital assets of $34.8\nmillion as of March 31, 2026. Subsequent to March 31, 2026, the Company\ndivested its digital asset holdings in full, selling 510 units for total cash\nproceeds of approximately $41.3 million, at an average price of approximately\n$80,980 per unit, which have been received by the Company.\n\nAs of May 31, 2026, the Company had estimated cash balances across its\naccounts of approximately $83.4 million. In addition, the Company held current\nfinancial assets measured at fair value through profit or loss, representing\ninvestments in investment funds, of approximately $50.2 million based on the\nlatest available valuations, and cash consideration held in escrow and\nholdback, recorded under other receivables, of approximately $6.1 million. As\nof May 31, 2026, the combined total of the Company’s estimated cash\nbalances, current financial assets measured at fair value through profit or\nloss, and cash consideration held in escrow and holdback, was approximately\n$139.7 million.\n\nReturning Capital to Shareholders\n\nOn March 6, 2026, the Company announced a $40 million share repurchase\nprogram. From program launch on March 6, 2026 through May 13, 2026, the\nCompany has repurchased 968,349 of its Class A Ordinary Shares in open-market\ntransactions for a total purchase price of approximately $19 million. The\nrepurchase program reflects the Board’s confidence in the long-term value of\nthe Company and complements continued investment in IM8’s growth\ninitiatives. The Company intends to continue executing repurchases under the\nauthorized program in a disciplined manner, subject to market conditions and\napplicable regulatory requirements.\n\nAdvancing Global Nutrition – Partnership with Vitamin Angels\n\nIn April 2026, Prenetics announced a global partnership between IM8 and\nVitamin Angels, a leading global public health nonprofit with a 31-year track\nrecord, a four-star Charity Navigator rating, and the infrastructure to reach\nmore than 74 million women and children annually across 65+ countries. Under\nthe partnership, IM8 has committed to impacting 400,000 pregnant women,\ninfants, and children under five in underserved communities during the first\nyear, with a long-term goal to impact millions of lives through sustained\nfunding and awareness. The partnership extends IM8’s mission beyond premium\nnutrition to address malnutrition among the world’s most vulnerable\npopulations.\n\nStrengthening IM8 Leadership for the Next Phase of Growth\n\nIM8 also strengthened its leadership team with the appointment of Brian J.\nRosin as Chief Financial Officer of IM8. Mr. Rosin is based in the United\nStates and brings significant experience across consumer health, e-commerce\noperations, finance, and strategic execution, having previously served as CFO\nof Wellbeam Consumer Health and NATURELO Premium Supplements. His appointment\nadds dedicated financial and operational leadership to support IM8’s next\nphase of global growth, disciplined execution, and strategic initiatives.\n\nOutlook\n\nIM8 generated revenue of approximately $30.7 million for the two months ended\nMay 31, 2026. The Company expects Q2 2026 revenue in the range of\napproximately $46 million to $48 million, with IM8 contributing approximately\n$44 million to $46 million, representing approximately 33% sequential\nquarterly growth for IM8. The Company is raising its full-year 2026 IM8\nrevenue guidance to $190 million to $210 million (previously $180 million to\n$200 million). These guidance ranges are consistent with those set out in the\nPreliminary Announcement and reflect management’s current estimates as of\nthe date of this announcement.\n\nAbout Prenetics\n\nPrenetics (NASDAQ: PRE) is a leading health sciences company dedicated to\nadvancing human health and longevity. The Company’s flagship consumer brand,\nIM8, co-founded with David Beckham and championed by World No. 1 tennis player\nAryna Sabalenka, is redefining the premium daily nutrition category through\nscience-backed formulations and global brand partnerships. Since its launch,\nIM8 has become one of the fastest-growing brands in consumer health, achieving\nan impressive milestone of surpassing $100 million in annualized recurring\nrevenue within just 11 months of operations, and is now sold in more than 40\ncountries worldwide.\n\nAbout IM8\n\nIM8 is the pinnacle of premium core nutrition, born from a collaboration\nbetween David Beckham as a co-founding partner, and an elite team of\nscientists spanning medical professionals, academia and space science.\nCombining cutting-edge science with nature’s most potent ingredients, IM8\ndelivers a holistic, science-backed approach to health, empowering you to live\nyour most vibrant life. IM8’s flagship product, Daily Ultimate Essentials\nPro, is an all-in-one powder supplement engineered to replace 16 different\nsupplements in a delicious drink and is NSF Certified for Sport, non-GMO,\nvegan, free from common allergens, and contains no artificial flavors, colors\nor sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading\nglobal health sciences company dedicated to advancing consumer health. To\nlearn more about IM8, please visit www.IM8health.com.\n\nInvestor Relations Contact\n\ninvestors@prenetics.com \nPRE@mzgroup.us \n\nAngela Cheung\nInvestor Relations / Corporate Finance\nangela.hm.cheung@prenetics.com \n\nForward-Looking Statements\n\nThis press release contains forward-looking statements. These statements are\nmade under the “safe harbor” provisions of the U.S. Private Securities\nLitigation Reform Act of 1995. Statements that are not historical facts,\nincluding statements about the Company’s goals, targets, projections,\noutlooks, beliefs, expectations, strategy, plans, objectives of management for\nfuture operations of the Company, and growth opportunities are forward-looking\nstatements. Our guidance reflects management’s current estimates and\nassumptions as of the date of this release, is subject to significant risks\nand uncertainties, and is not a guarantee of future performance. Actual\nresults may differ materially. In some cases, forward-looking statements can\nbe identified by words or phrases such as “may,” “will,” “expect,”\n“anticipate,” “target,” “aim,” “estimate,” “intend,”\n“plan,” “believe,” “potential,” “continue,” “is/are likely\nto,” “guidance,” “outlook,” “forecast,” or other similar\nexpressions. Forward-looking statements are based upon estimates and forecasts\nand reflect the views, assumptions, expectations, and opinions of the Company,\nwhich involve inherent risks and uncertainties, and therefore they should not\nbe relied upon as being necessarily indicative of future results. A number of\nfactors could cause actual results to differ materially from those contained\nin any forward-looking statement, including but not limited to: the Company\nmay not be able to maintain and enhance its IM8 business and brand if it\nsuffers negative publicity or fails to maintain a strong base of engaged\ncustomers and content creators, or otherwise fails to meet customers’\nexpectations; the Company’s ability to further develop and grow its\nbusiness, including new products and services; and its ability to identify and\nexecute on M&A opportunities. In addition to the foregoing factors, you should\nalso carefully consider the other risks and uncertainties described in the\n“Risk Factors” section of the Company’s most recent registration\nstatement and the prospectus therein, and the other documents filed by the\nCompany from time to time with the U.S. Securities and Exchange Commission.\nUnless otherwise specified, all information provided in this press release is\nas of the date of this press release, and the Company does not undertake any\nduty to update such information, except as required under applicable law.\nNothing in this press release constitutes an offer to sell, or the\nsolicitation of an offer to buy, any securities of the Company.\n\nBasis of Presentation\n\nFigures for prior periods have been re-presented in accordance with IFRS 5\nNon-current Assets Held for Sale and Discontinued Operations (“IFRS 5”).\nAs part of the Group’s strategic repositioning to focus its resources and\ncapital allocation on its core consumer health and prevention businesses, the\nGroup has divested or exited certain non-core businesses and investments,\nincluding ACT Genomics, Europa and Insighta.\n\nIn June 2025, the Group determined that ACT Genomics Holdings Company Limited\n(“ACT Genomics”) met the criteria to be classified as held for sale and a\ndiscontinued operation, following the signing of a definitive sale and\npurchase agreement with Delta Electronics, Inc. The divestment of ACT Genomics\nwas completed on October 1, 2025, and its results have been excluded from the\nGroup’s continuing operations thereafter.\n\nThe Group also completed the divestiture of substantially all of the assets of\nits Europa business in January 2026. Accordingly, Europa’s results are\nincluded in the Group’s financial results only up to the date of completion\nof the divestiture and are excluded from the Group’s continuing operations\nthereafter.\n\nIn February 2026, the Group completed the disposal of its remaining equity\ninterest in Insighta Holdings Limited (“Insighta”). Accordingly, the\nGroup’s share of results from Insighta is included only up to the date of\ncompletion of the disposal.\n\nIn accordance with IFRS 5, the results of discontinued operations are\npresented separately from the Group’s continuing operations (comprising IM8\nand CircleDNA) in the unaudited consolidated statements of profit or loss and\nother comprehensive income, and comparative figures for those statements have\nbeen re-presented accordingly.\n\nThe financial information presented in this press release was unaudited.\nUnaudited non-IFRS financial measures have been provided in this press\nrelease. An explanation of these measures is also included below under the\nheading “Unaudited Non-IFRS Financial Measures”.\n\nUnaudited Non-IFRS Financial Measures\n\nTo supplement the Company’s consolidated financial statements prepared in\naccordance with IFRS Accounting Standards, the Company is providing the\nfollowing non-IFRS measures: EBITDA and adjusted EBITDA. These non-IFRS\nfinancial measures are not based on any standardized methodology prescribed by\nIFRS Accounting Standards and are not necessarily comparable to\nsimilarly-titled measures presented by other companies. Management believes\nthese non-IFRS financial measures are useful to investors in evaluating the\nCompany’s ongoing operating results and trends.\n\nEBITDA is defined as net loss before (1) depreciation and amortization, (2)\ninterest income, (3) other finance costs, and (4) income tax expense.\n\nAdjusted EBITDA is defined as EBITDA further adjusted to exclude (1)\namortization of deferred expenses, (2) equity-settled share-based payment\nexpenses, (3) non-recurring expenses related to acquisition, disposal and\nfundraising, (4) strategic realignment expenses, (5) exchange gain or loss,\nnet, (6) fair value loss/(gain) on financial assets at fair value through\nprofit or loss, (7) fair value loss on warrant liabilities, (8) gain on\nwarrant exchange, (9) unrealized fair value loss on digital asset, and (10)\n(profit)/loss from discontinued operations, net of tax.\n\nIn addition, other companies, including companies in the same industry, may\nnot use the same non-IFRS measures or may calculate these metrics in a\ndifferent manner than management, or may use other financial measures to\nevaluate their performance, all of which could reduce the usefulness of these\nnon-IFRS measures as comparative measures. Because of these limitations, the\nCompany’s non-IFRS financial measures should not be considered in isolation\nfrom, or as a substitute for, financial information prepared in accordance\nwith IFRS Accounting Standards.\n\nInvestors are encouraged to review the breakdown provided in the non-IFRS\nreconciliation set forth in the below table captioned “Reconciliation of\nloss for the period under IFRS Accounting Standards and adjusted EBITDA\n(Non-IFRS).”\n\nPRENETICS GLOBAL LIMITED\nUnaudited consolidated statements of financial position\n(All amounts in thousands of U.S. dollars (“$”))\n\n March 31, December 31, \n 2026 2025 \n (Unaudited) (Audited) \n Assets \n Property, plant and equipment $ 594 $ 1,763 \n Intangible assets 40 66 \n Digital assets 34,799 44,629 \n Goodwill — 1,379 \n Interests in equity-accounted investees — 66,109 \n Financial assets at fair value through profit or loss - non-current 2,338 252 \n Other non-current assets 5,423 6,678 \n Non-current assets 43,194 120,876 \n Inventories 14,198 7,032 \n Trade receivables 2,529 2,978 \n Deposits, prepayments and other receivables 9,346 11,860 \n Amount due from a related company — 4 \n Financial assets at fair value through profit or loss - current 50,018 31,192 \n Cash and cash equivalents 56,017 32,131 \n Current assets 132,108 85,197 \n Total assets $ 175,302 $ 206,073 \n Liabilities \n Deferred tax liabilities $ 8 $ 8 \n Warrant liabilities 28,354 20,319 \n Lease liabilities - non-current 50 437 \n Other non-current liabilities 228 230 \n Non-current liabilities 28,640 20,994 \n Trade payables 1,961 3,142 \n Accrued expenses and other current liabilities 20,293 21,124 \n Contract liabilities 2,948 3,086 \n Lease liabilities - current 407 1,330 \n Tax payable 31 31 \n Current liabilities 25,640 28,713 \n Total liabilities 54,280 49,707 \n Equity \n Class A ordinary shares 23 23 \n Class B ordinary shares 2 2 \n Reserves 121,090 156,434 \n Total equity attributable to equity shareholders of the Company 121,115 156,459 \n Non-controlling interests (93 (93 \n Total equity 121,022 156,366 \n Total equity and liabilities $ 175,302 $ 206,073 \n \n\nPRENETICS GLOBAL LIMITED\nUnaudited consolidated statements of profit or loss and other comprehensive\nincome\n(All amounts in thousands of U.S. dollars (“$”) unless otherwise\nindicated)\n\n Three Months Ended \n March 31, December 31, March 31, \n 2026 2025 2025 \n (Unaudited) (Unaudited) (Unaudited) \n Continuing operations \n Revenue $ 35,954 $ 33,288 $ 8,275 \n Direct costs (12,671 ) (11,911 ) (2,668 ) \n Gross profit 23,283 21,377 5,607 \n Other income and other net gain 840 212 204 \n Selling and marketing expenses (4) (22,205 ) (16,090 ) (4,126 ) \n Research and development expenses (4) (1,443 ) (743 ) (2,007 ) \n Administrative and other operating expenses (4) (9,341 ) (16,270 ) (5,649 ) \n Loss from operations (8,866 ) (11,514 ) (5,971 ) \n Fair value (loss)/gain on financial assets at fair value through profit or loss (568 ) 879 — \n Gain on warrant exchange — 36,657 — \n Fair value loss on warrant liabilities (8,035 ) (17,339 ) (63 ) \n Unrealized fair value loss on digital assets (9,830 ) (9,725 ) — \n Other finance costs (9 ) (12 ) (18 ) \n Loss before taxation (27,308 ) (1,054 ) (6,052 ) \n Income tax expense (28 ) (37 ) (20 ) \n Loss from continuing operations (27,336 ) (1,091 ) (6,072 ) \n Discontinued operation \n Profit/(loss) from discontinued operation, net of tax (5) 4,231 (6,451 ) (4,944 ) \n Loss for the period (23,105 ) (7,542 ) (11,016 ) \n Other comprehensive (expense)/income for the period \n Items that will not be reclassified subsequently to profit or loss: \n Share of other comprehensive (expense)/income of equity-accounted investees (167 ) 40 (36 ) \n Unrealized fair value loss on digital asset — (1,351 ) — \n Item that may be reclassified subsequently to profit or loss: \n Reclassification of cumulative translation reserve upon disposal of foreign operations — (74 ) — \n Exchange difference on translation of foreign operations (198 ) 328 103 \n Other comprehensive (expense)/income for the period (365 ) (1,057 ) 67 \n Total comprehensive expense for the period $ (23,470 ) $ (8,599 ) $ (10,949 ) \n Loss attributable to: \n Equity shareholders of Prenetics $ (23,104 ) $ (7,500 ) $ (10,390 ) \n Non-controlling interests — (42 ) (626 ) \n $ (23,104 ) $ (7,542 ) $ (11,016 ) \n Total comprehensive expense attributable to: \n Equity shareholders of Prenetics $ (23,470 ) $ (8,592 ) $ (10,243 ) \n Non-controlling interests — (7 ) (706 ) \n $ (23,470 ) $ (8,599 ) $ (10,949 ) \n Loss per share: \n Basic $ (1.36 ) $ (0.47 ) $ (0.80 ) \n Diluted (1.36 ) (0.47 ) (0.80 ) \n Loss per share - Continuing operations: \n Basic (1.61 ) (0.07 ) (0.44 ) \n Diluted (1.61 ) (0.07 ) (0.44 ) \n Weighted average number of common shares: \n Basic 16,982,575 16,034,309 13,003,881 \n Diluted 16,982,575 16,034,309 13,003,881 \n \n\nPRENETICS GLOBAL LIMITED\nUnaudited consolidated statements of cash flows\n(All amounts in thousands of U.S. dollars (“$”))\n\n Three Months Ended \n March 31, March 31, \n 2026 2025 \n (Unaudited ) (Unaudited ) \n Cash flows from operating activities \n Loss for the year (23,105 ) (11,016 ) \n Adjustments for: \n Bank interest income (294 ) (440 ) \n Depreciation 159 893 \n Amortization of intangible assets 25 239 \n Other finance costs 9 69 \n Fair value loss on financial assets at fair value through profit or loss 568 — \n Fair value loss on warrant liabilities 8,035 63 \n Unrealized fair value loss on digital asset 9,830 — \n Net foreign exchange losses (20 ) (196 ) \n Gain on disposal of assets (253 ) — \n Write-off on inventories (32 ) 667 \n Gain on disposal of an equity-accounted investee (4,172 ) — \n Share of loss of equity-accounted investees 113 309 \n Equity-settled share-based payment expenses 1,242 1,119 \n Income tax expense/(credit) 28 (64 ) \n (7,867 ) (8,357 ) \n Changes in: \n Decrease in deferred expenses — 2,057 \n Increase in inventories (7,134 ) (711 ) \n Decrease in trade receivables 451 779 \n (Increase)/decrease in deposits, prepayments and other receivables 2,874 1,043 \n Decrease in amounts due from related companies 4 — \n Decrease in other non-current assets 1,255 118 \n (Decrease)/increase in trade payables (1,179 ) 469 \n (Decrease)/increase in accrued expenses and other current liabilities (358 ) 926 \n Decrease in contract liabilities (138 ) (300 ) \n Decrease in other non-current liabilities (4 ) (1 ) \n Cash used in operating activities (12,096 ) (3,977 ) \n Income taxes paid (28 ) — \n Net cash used in operating activities (12,124 ) (3,977 ) \n Cash flows from investing activities \n Payment for purchase of financial assets at fair value through profit or loss (19,876 ) — \n Net cash inflow from disposal of an equity-accounted investee 69,000 — \n Interest received 294 440 \n Net cash from investing activities 49,418 440 \n Cash flows from financing activities \n Capital element of lease rentals paid (142 ) (622 ) \n Interest element of lease rentals paid (9 ) (69 ) \n Proceeds from public placement (13,117 ) — \n Net cash used in financing activities (13,268 ) (691 ) \n Net increase/(decrease) in cash and cash equivalents 24,026 (4,228 ) \n Cash and cash equivalents at the beginning of the period 32,131 52,251 \n Effect of foreign exchange rate changes (140 ) (57 ) \n Cash and cash equivalents at the end of the period 56,017 47,966 \n \n\nPRENETICS GLOBAL LIMITED\nUnaudited Non-IFRS Financial Measures\n(All amounts in thousands of U.S. dollars (“$”))\n\nReconciliation of loss for the period under IFRS Accounting Standards and\nadjusted EBITDA (Non-IFRS)\n\n Three Months Ended \n March 31, December 31, March 31, \n 2026 2025 2025 \n (Unaudited ) (Unaudited ) (Unaudited ) \n Loss for the period under IFRS Accounting Standards $ (23,104 ) $ (7,542 ) $ (11,016 ) \n Depreciation and amortization 184 273 326 \n Interest income (294 ) (210 ) (422 ) \n Other finance costs 9 12 18 \n Income tax expense 28 37 20 \n EBITDA (23,177 ) (7,430 ) (11,074 ) \n Amortization of deferred expenses — — 2,057 \n Equity-settled share-based payment expenses 1,242 1,299 1,167 \n Non-recurring expenses related to acquisition, disposal and fundraising 953 4,366 126 \n Strategic realignment expenses 1,252 3,750 2 \n Exchange gain or loss, net (71 ) 200 276 \n Fair value loss/(gain) on financial assets at fair value through profit or loss 568 (879 ) — \n Fair value loss on warrant liabilities 8,035 17,339 63 \n Gain on warrant exchange — (36,657 ) — \n Unrealized fair value loss on digital assets 9,830 9,725 — \n (Profit)/loss from discontinued operation, net of tax (4,231 ) 6,451 4,944 \n Adjusted EBITDA $ (5,599 ) $ (1,836 ) $ (2,439 ) \n \n\n\n\n Three Months Ended \n March 31, December 31, March 31, \n 2026 2025 2025 \n (Unaudited) (Unaudited) (Unaudited) \n Continuing operations \n Selling and marketing expenses $ 27 $ 24 $ 1 \n Research and development expenses 226 90 467 \n Administrative and other operating expenses 746 444 456 \n Total employee equity-settled share-based payment expenses $ 999 $ 558 $ 924 \n \n\n(1 )EBITDA is a non-IFRS financial measure used by us to measure the strength\nof our core financial and operating performance. EBITDA excludes (1)\ndepreciation and amortization, (2) interest income, (3) other finance costs,\nand (4) income tax expense. For more information regarding this non-IFRS\nfinancial measure, see \"Unaudited Non-IFRS Financial Measures.\"\n(2 )Adjusted EBITDA is a non-IFRS financial measure used by us to measure the\nstrength of our core financial and operating performance. Adjusted EBITDA\nrepresents EBITDA further adjusted to exclude (1) amortization of deferred\nexpenses, (2) equity-settled share-based payment expenses, (3) non-recurring\nexpenses related to acquisition, disposal and fundraising, (4) strategic\nrealignment expenses, (5) exchange gain or loss, net, (6) fair value\nloss/(gain) on financial assets at fair value through profit or loss, (7) fair\nvalue loss on warrant liabilities, (8) gain on warrant exchange, (9)\nunrealized fair value loss on digital asset, and (10) (profit)/loss from\ndiscontinued operations, net of tax. These adjustments are made for items that\nmay not be indicative of our business performance, including non-cash and/or\nnon-recurring items. For more information regarding this non-IFRS financial\nmeasure, see \"Unaudited Non-IFRS Financial Measures.\"\n(3 )The Company uses annualized recurring revenue (“ARR”) as a key\noperating metric and is calculated by multiplying the monthly revenue from the\nlast month of a given period by 12.\n(4) Includes equity-settled share-based payment expenses from continuing\noperations as follows:\n(5) ACT Genomics, Europa and Insighta are classified as discontinued\noperations in accordance with IFRS 5. The results of the discontinued\noperations have been presented separately from the continuing operations in\nthe consolidated statements of profit or loss and other comprehensive income.\n\nA photo accompanying this announcement is available at\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/1a9e11ac-9f38-4820-84e0-218e21ce0f7d\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/106dbe1a-a6e1-49d9-97a2-c5609258bdc7)\nIM8 Monthly Revenue ($M) \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1a9e11ac-9f38-4820-84e0-218e21ce0f7d/en)\n~42x ARR Growth\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-10T12:30:01.055210972Z","server_sent_at_ms":1781094601055},"received_at":"2026-06-10T12:30:01.385Z","source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309702/0/en/Prenetics-Announces-Record-Q1-2026-Results-with-IM8-Revenue-Reaching-a-Record-16-7-Million-in-May-Implying-200-Million-in-Annualized-Recurring-Revenue.html"},"analysis":{"id":"49525","press_release_id":"60095","analysis_json":{"industry":{"label":"Food, Beverage & Tobacco","sector":"Consumer Staples"},"redFlags":["Net loss includes significant non-cash fair-value adjustments on digital assets and warrants","Company holds substantial exposure to digital assets (Bitcoin) which creates volatility in reported earnings","High selling and marketing expenses ($22.2M) relative to revenue ($36.0M)"],"eventType":"earnings","narrative":"Prenetics reported Q1 2026 revenue of $36.0 million, driven by IM8 revenue of $33.8 million which grew nearly 6x year-over-year and 23% sequentially.\n\nThe company raised its full-year 2026 IM8 revenue guidance to $190M-$210M, citing strong momentum with May 2026 monthly revenue hitting a record $16.7M, implying $200M in annualized recurring revenue.\n\nWhile the company reported a net loss of $23.1M, this was driven by non-cash fair-value losses on digital assets and warrants; core operating loss was $8.9M with gross margin expanding to 65%.\n\nPrenetics divested its digital asset holdings for $41.3M, bringing total liquidity to $139.7M, and has repurchased $19M of shares under its $40M buyback program.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"IM8 breakout: 6x YoY growth, raised guidance, and $200M ARR run rate backed by strong liquidity and buybacks."},"keyFigures":{"revenue":35954000,"guidance":"FY26 IM8 revenue $190M-$210M (raised from $180M-$200M); Q2 total revenue $46M-$48M","revenueYoy":"333%","customDimensions":{"gross_margin":"65%","gross_profit":23283000,"im8_revenue_q1":33782000,"im8_arr_implied":200000000,"im8_may_revenue":16700000,"im8_revenue_seq":"23.1%","im8_revenue_yoy":"489%","repurchase_cost":19000000,"im8_gross_margin":"64%","shares_repurchased":968349,"cash_and_equivalents":56017000,"total_liquidity_may31":139700000,"digital_asset_proceeds":41300000}},"quotedText":"The momentum behind IM8 is extraordinary. Q1 2026 was a defining quarter — IM8 revenue grew nearly 6x year-over-year and 23.1% sequentially over Q4 2025, and our quarterly subscription strategy delivered a step-change in customer economics.","namedEntities":{"people":[{"name":"Danny Yeung","role":"CEO and Co-Founder"},{"name":"Brian J. Rosin","role":"CFO of IM8"},{"name":"David Beckham","role":"Co-founding partner"},{"name":"Aryna Sabalenka","role":"Athlete partner"},{"name":"Ollie Bearman","role":"Athlete partner"},{"name":"Giannis Antetokounmpo","role":"Athlete partner"},{"name":"Lionel Messi","role":"Athlete partner"}],"products":["Daily Ultimate Essentials Pro","Daily Ultimate Longevity","Beckham Stack"],"companies":[{"name":"Prenetics Global Limited","ticker":"PRE"},{"name":"IM8","relationship":"subsidiary/brand"},{"name":"Inter Miami CF","relationship":"partner"},{"name":"Vitamin Angels","relationship":"partner"},{"name":"Delta Electronics, Inc.","relationship":"acquirer of discontinued operation"}],"dollarAmounts":[{"amount":"$36.0 million","context":"Q1 2026 total revenue"},{"amount":"$33.8 million","context":"Q1 2026 IM8 revenue"},{"amount":"$27.4 million","context":"Q4 2025 IM8 revenue"},{"amount":"$5.7 million","context":"Q1 2025 IM8 revenue"},{"amount":"$190 million to $210 million","context":"FY26 IM8 revenue guidance"},{"amount":"$180 million to $200 million","context":"Prior FY26 IM8 revenue guidance"},{"amount":"$46 million to $48 million","context":"Q2 2026 total revenue guidance"},{"amount":"$44 million to $46 million","context":"Q2 2026 IM8 revenue guidance"},{"amount":"$41.3 million","context":"Proceeds from digital asset divestment"},{"amount":"$80,980","context":"Average price per digital asset unit"},{"amount":"$16.7 million","context":"IM8 monthly revenue in May 2026"},{"amount":"$200 million","context":"Implied annualized recurring revenue"},{"amount":"$23.1 million","context":"Net loss for the period"},{"amount":"$9.8 million","context":"Unrealized fair-value loss on digital assets"},{"amount":"$8.0 million","context":"Fair-value loss on warrant liabilities"},{"amount":"$56.0 million","context":"Cash and cash equivalents as of March 31, 2026"},{"amount":"$139.7 million","context":"Total liquidity as of May 31, 2026"},{"amount":"$40 million","context":"Authorized share repurchase program"},{"amount":"$19 million","context":"Cost of shares repurchased to date"}]},"materialImpact":{"score":4,"reasoning":"Strong Q1 results with IM8 revenue up nearly 6x YoY and gross margin expansion. Management raised full-year guidance. The net loss is driven by non-cash fair-value adjustments on digital assets and warrants, not core operations. Active share repurchases signal confidence."},"tickerRelevance":{"others":[],"primary":"PRE"},"globalImportance":35,"audienceRelevance":40,"eventTypeSecondary":["guidance_update","buyback","executive_change"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"earnings_beat_guidance_raise","sectorWeight":"consumer_health","householdBrandBoost":"David Beckham/IM8 association","retailFavoriteBoost":"moderate"}},"event_type":"earnings","event_type_secondary":["guidance_update","buyback","executive_change"],"sentiment":"bullish","material_impact_score":4,"narrative":"Prenetics reported Q1 2026 revenue of $36.0 million, driven by IM8 revenue of $33.8 million which grew nearly 6x year-over-year and 23% sequentially.\n\nThe company raised its full-year 2026 IM8 revenue guidance to $190M-$210M, citing strong momentum with May 2026 monthly revenue hitting a record $16.7M, implying $200M in annualized recurring revenue.\n\nWhile the company reported a net loss of $23.1M, this was driven by non-cash fair-value losses on digital assets and warrants; core operating loss was $8.9M with gross margin expanding to 65%.\n\nPrenetics divested its digital asset holdings for $41.3M, bringing total liquidity to $139.7M, and has repurchased $19M of shares under its $40M buyback program.","key_figures":{"revenue":35954000,"guidance":"FY26 IM8 revenue $190M-$210M (raised from $180M-$200M); Q2 total revenue $46M-$48M","revenueYoy":"333%","customDimensions":{"gross_margin":"65%","gross_profit":23283000,"im8_revenue_q1":33782000,"im8_arr_implied":200000000,"im8_may_revenue":16700000,"im8_revenue_seq":"23.1%","im8_revenue_yoy":"489%","repurchase_cost":19000000,"im8_gross_margin":"64%","shares_repurchased":968349,"cash_and_equivalents":56017000,"total_liquidity_may31":139700000,"digital_asset_proceeds":41300000}},"named_entities":{"people":[{"name":"Danny Yeung","role":"CEO and Co-Founder"},{"name":"Brian J. Rosin","role":"CFO of IM8"},{"name":"David Beckham","role":"Co-founding partner"},{"name":"Aryna Sabalenka","role":"Athlete partner"},{"name":"Ollie Bearman","role":"Athlete partner"},{"name":"Giannis Antetokounmpo","role":"Athlete partner"},{"name":"Lionel Messi","role":"Athlete partner"}],"products":["Daily Ultimate Essentials Pro","Daily Ultimate Longevity","Beckham Stack"],"companies":[{"name":"Prenetics Global Limited","ticker":"PRE"},{"name":"IM8","relationship":"subsidiary/brand"},{"name":"Inter Miami CF","relationship":"partner"},{"name":"Vitamin Angels","relationship":"partner"},{"name":"Delta Electronics, Inc.","relationship":"acquirer of discontinued operation"}],"dollarAmounts":[{"amount":"$36.0 million","context":"Q1 2026 total revenue"},{"amount":"$33.8 million","context":"Q1 2026 IM8 revenue"},{"amount":"$27.4 million","context":"Q4 2025 IM8 revenue"},{"amount":"$5.7 million","context":"Q1 2025 IM8 revenue"},{"amount":"$190 million to $210 million","context":"FY26 IM8 revenue guidance"},{"amount":"$180 million to $200 million","context":"Prior FY26 IM8 revenue guidance"},{"amount":"$46 million to $48 million","context":"Q2 2026 total revenue guidance"},{"amount":"$44 million to $46 million","context":"Q2 2026 IM8 revenue guidance"},{"amount":"$41.3 million","context":"Proceeds from digital asset divestment"},{"amount":"$80,980","context":"Average price per digital asset unit"},{"amount":"$16.7 million","context":"IM8 monthly revenue in May 2026"},{"amount":"$200 million","context":"Implied annualized recurring revenue"},{"amount":"$23.1 million","context":"Net loss for the period"},{"amount":"$9.8 million","context":"Unrealized fair-value loss on digital assets"},{"amount":"$8.0 million","context":"Fair-value loss on warrant liabilities"},{"amount":"$56.0 million","context":"Cash and cash equivalents as of March 31, 2026"},{"amount":"$139.7 million","context":"Total liquidity as of May 31, 2026"},{"amount":"$40 million","context":"Authorized share repurchase program"},{"amount":"$19 million","context":"Cost of shares repurchased to date"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-10T12:37:22.010Z","global_importance":35,"audience_relevance":40,"importance_components":{"tickerTier":"small-cap","eventGravity":"earnings_beat_guidance_raise","sectorWeight":"consumer_health","householdBrandBoost":"David Beckham/IM8 association","retailFavoriteBoost":"moderate"}},"durationMs":76809,"modelName":"george-droid-qwen-72b"}}